Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2
NCT05514717Phase 1Terminated
- Sponsor
- Day One Biopharmaceuticals
- Start
- Jan 2023
- Primary completion
- May 2026
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of calotatug ginistinag in solid tumor, sponsored by Day One Biopharmaceuticals. Primary endpoints: Frequency of dose-limiting toxicities at 15 months, Incidence of adverse events at 3 years and 1 more. Started Jan 2023; status: terminated.
02
Drugs
calotatug ginistinag
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05514717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05514717.